News on cancer research & diagnostics, liquid biopsy, and cancer risk testing.
Novartis' alpelisib is the first PI3K inhibitor approved for advanced or metastatic breast cancer patients who harbor PIK3CA mutations.
The companies are developing PET tracers based on Indi's affinity agent technology that will allow for imaging-based detection of cytotoxic T lymphocyctes.
The California-based health system is expanding its partnership with clinical decision support vendor CancerIQ to integrate risk assessment into the Cerner EHR workflow.
Using exome sequencing, the team developed a transgenic model with altered orthologs of nine genes and found a combination of drugs that could act as a cancer treatment option.
The company will now be able to market the test, which algorithmically weighs molecular markers and clinical information, in all 50 US states.
